Internal Medicine, Hematology & Oncology · Belleville, NJ
NPI
1780676759
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
1 Clara Maass Dr Ste 200
Belleville, NJ, 07109
Phone (973) 751-8880
Groups this clinician bills Medicare through
Medicare paid, 2024
$524K
33,502 services
Medicare patients, 2024
145
Average age 72
Drug cost, 2024
$963K
468 prescriptions
Company payments, 2025
$1,233
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sitamahalakshmi Yerramalli was code 36415 (venipuncture blood collection), 487 times for 133 patients. In total Sitamahalakshmi Yerramalli billed 33,502 services in 41 codes, and Medicare paid $524K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-28.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 487 | 133 | $8.65 | $4,213 |
| 85025 Blood Count | Office | 474 | 129 | $7.61 | $3,607 |
| 99214 Office E&M - Established | Office | 364 | 126 | $105.41 | $38K |
| 96372 Injection Administration | Office | 94 | 16 | $12.44 | $1,170 |
| 96365 Intravenous Infusion, Hydration | Office | 36 | 11 | $50.71 | $1,826 |
| 99204 Office E&M - New | Office | 30 | 30 | $133.83 | $4,015 |
| 99213 Office E&M - Established | Office | 23 | 19 | $72.18 | $1,660 |
By year: 2022 $528K for 63,915 services; 2023 $529K for 49,345 services; 2024 $524K for 33,502 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 487 | 133 | $8.65 | $4,213 |
| 85025 Blood Count | 474 | 129 | $7.61 | $3,607 |
Medicare prescription drug claims, 2024
In 2024, the drug Sitamahalakshmi Yerramalli prescribed most often to Medicare patients was Eliquis (Apixaban), with 32 prescriptions and refills. In total Sitamahalakshmi Yerramalli wrote 468 Medicare prescriptions that cost $963K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 32 | 38 | Under 11 | $21K |
| Hydroxyurea Generic | 24 | 51 | Under 11 | $1,335 |
| Procrit Epoetin Alfa | 19 | 19 | Under 11 | $56K |
| Ciprofloxacin-D5w Ciprofloxacin In 5 % Dextrose | 15 | 15 | Under 11 | $340 |
| Risperidone Generic | 15 | 15 | Under 11 | $220 |
| Keytruda Pembrolizumab | 14 | 14 | Under 11 | $160K |
| Pantoprazole Sodium Generic | 14 | 14 | Under 11 | $201 |
| Mirtazapine Generic | 12 | 12 | Under 11 | $835 |
| Donepezil Hcl Generic | 12 | 12 | Under 11 | $208 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 12 | 12 | Under 11 | $91K |
| Levothyroxine Sodium Generic | 12 | 32 | Under 11 | $117 |
| Nifedipine Er Nifedipine | 11 | 11 | Under 11 | $209 |
| Clopidogrel Clopidogrel Bisulfate | 11 | 11 | Under 11 | $157 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 11 | 11 | Under 11 | $117K |
| Potassium Chloride Generic | 11 | 11 | Under 11 | $1,231 |
Brand drugs: 149 claims; generic drugs: 319 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sitamahalakshmi Yerramalli $1,233 ($1,233 in general payments such as food, travel and fees) from 31 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $120.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $120 |
| Adaptive Biotechnologies Corporation ADPT | 4 | $92.33 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $88.94 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $88.81 |
| Daiichi Sankyo Inc. 4568.T | 4 | $73.27 |
| Janssen Biotech, Inc. JNJ | 4 | $70.96 |
| GlaxoSmithKline, LLC. GSK | 3 | $58.17 |
| Karyopharm Therapeutics Inc. KPTI | 3 | $54.46 |
| Pfizer Inc. PFE | 3 | $50.93 |
| Incyte Corporation INCY | 3 | $49.21 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.